Pharmacokinetic study of KW-6485P for pediatric patients

Kyowa Hakko Kirin Co., Ltd.0 个研究点目标入组 25 人开始时间: 2009年9月9日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who have been diagnosed with symptomatic or cryptogenic localization related epilepsy
•Patients who have simple partial seizure, complex partial seizure, or secondarily generalized seizure
•Patients who have provided written informed consent from guardian
•Patients who experience partial seizure regardless of the treatment of other antiepileptic drugs
•Patients who have no progressive disease of central nervous system with imaging diagnosis

•Patients with seizures secondarily to a treatable diseases
•Patients with seizures other than partial seizures
•Patients with a serious disorder of cardiac, hepatic, renal, pulmonary, hematologic, metabolic, or endocrinologic system
•Patients with a progressive neurological disorder
•Patients with a complication or history of severe psychiatric symptom
•Patients with a history of renal or urinary calculus
•Patients with a complication or history of angle-closure glaucoma

发起方

Kyowa Hakko Kirin Co., Ltd.